Parvovirus B19 pneumonia in a child undergoing allogeneic hematopoietic stem cell transplantation

Beske, Florian; Modrow, Susanne; Sørensen, Jan Tind; Schmidt, Helmut; Kriener, Susanne; Allwinn, Regina; Klingebiel, Thomas; Schwabe, Dirk; Lehrnbecher, Thomas

doi:10.1038/sj.bmt.1705693

Cited by 17 publications

(14 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,59 The infection has been seen in association with other post-transplant complications, such as allograft dysfunction, hepatitis, myocarditis and glomerulonephritis, and post-transplant mortality directly attributable to B19V has been estimated at 3%. 10,57 B19V exanthema can also mimic cutaneous acute GVHD (aGVHD). 12,60 In our study none of the patients with B19V viremia had any specific signs or suspicion of B19V infection.…”

Section: Discussionmentioning

confidence: 99%

“…Allogeneic HSCT patients are at a particular risk for B19V infection, which may lead to severe, persistent and usually nonspecific illness. [10][11][12][13] A few studies address the incidence and clinical spectrum of B19V infections among HSCT patients; however, large prospective studies among the pediatric population are lacking. B19V infections can be severe after allogeneic HSCT and in addition to aplastic crises 14 cause pneumonia 10 and multiorgan failure.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT

Rahiala

Koskenvuo

Norja

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

Among the immunocompetent, infections with parvovirus B19 (B19V) and human bocavirus (HBoV) 1 range clinically from asymptomatic to severe, while following allogeneic hematopoietic SCT (HSCT) B19V can cause a persistent severe illness. The epidemiology and clinical impact of HBoV1 and the other emerging parvovirus 4 (PARV4) among immunocompromised patients have not been established. To determine the occurrence and clinical spectrum of B19V, PARV4 and HBoV1 infections, we performed a longitudinal molecular surveillance among 53 allogeneic HSCT recipients for pre-and post-HSCT DNAemias of these parvoviruses. Quantitative real-time PCR showed B19V DNA in sera of 16 (30%) patients, at mean levels of 4.6 Â 10 3 , 9.9 Â 10 7 , 1.1 Â 10 10 and 1.6 Â 10 2 B19V DNA copies/mL pre-HSCT (9/53), and at 1 (6/53), 2 (4/53) and 3 months (1/25) post HSCT, respectively. However, no clinical manifestation correlated with the presence of B19V viremia. All B19V sequences were of genotype 1. None of the sera investigated contained PARV4 or HBoV1 DNAs. Our data demonstrate B19V viremia to be frequent among pediatric allogeneic HSCT recipients, yet without apparent clinical correlates. PARV4 or HBoV1 viremias were not seen in these immunocompromised patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT

Rahiala

Koskenvuo

Norja

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…111 There are also reports of pneumonitis in transplant recipients. 112,113 Infection in transplant recipients is unlike that of immunocompetent patients in that viral replication can persist for prolonged periods of time. 114 Parvovirus has well-established association with hematologic abnormalities including pure red cell aplasia and acute or chronic anemia in transplant recipients.…”

Section: Parvovirus B19mentioning

confidence: 99%

Respiratory Viral Infections in Transplant and Oncology Patients

Kumar

Humar

2010

Infectious Disease Clinics of North America

View full text Add to dashboard Cite

Respiratory viral infections are a significant cause of morbidity and mortality in the immunocompromised host. In the last two decades, there has been significant advancement in the epidemiology and laboratory diagnosis of respiratory viral infections. In addition, the clinical consequences of many respiratory viruses in the immunocompetent and immunocompromised host continue to be studied. Many therapeutics have also now become available, although their efficacy in transplant recipients remains uncertain. This article describes the current knowledge about respiratory viral infections as it relates to solid organ transplant, hematopoietic stem cell transplant, and oncology settings.

show abstract

“…Little is known about the manifestations of B19 in cancer patients and SCT recipients , and no studies have evaluated the preemptive application of IVIG to prevent delays in antineoplastic therapy or correlated response to IVIG with levels of B19 by quantitative PCR (qPCR). We herein describe 6 consecutive patients with multiple myeloma (MM) who had undergone melphalan‐based autologous SCT (MEL‐ASCT) and developed B19 disease, with emphasis on the role of preemptive IVIG in allowing the safe administration of antineoplastic therapy despite ongoing B19 disease.…”

mentioning

confidence: 99%

Preemptive intravenous immunoglobulin allows safe and timely administration of antineoplastic therapies in patients with multiple myeloma and parvovirus B19 disease

Katragadda

Shahid

Restrepo

et al. 2013

Transplant Infectious Dis

View full text Add to dashboard Cite

Parvovirus B19 can cause severe disease in myeloma patients including ASCT recipients. Thrombocytopenia - not anemia - was the leading presentation and may be associated with autoimmune conditions. Patients with unexplained cytopenias, particularly when prolonged, should undergo testing for circulating parvovirus. A reduction in viral load was associated with response to IVIG, although additional therapy was needed for recurrent disease. Most importantly, preemptive IVIG allowed for safe and timely administration of antineoplastic therapy in patients with ongoing B19 disease.

show abstract

Parvovirus B19 pneumonia in a child undergoing allogeneic hematopoietic stem cell transplantation

Cited by 17 publications

References 9 publications

Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT

Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT

Respiratory Viral Infections in Transplant and Oncology Patients

Preemptive intravenous immunoglobulin allows safe and timely administration of antineoplastic therapies in patients with multiple myeloma and parvovirus B19 disease

Contact Info

Product

Resources

About